Details of the Drug

General Information of Drug (ID: DMK8U72)

Drug Name
Labetalol
Synonyms
Albetol; Ibidomide; Labetalolum; Labetolol; NORMOZIDE; AH 5158; AH-5158; Labetalol (INN); Labetalol [INN:BAN]; Labetalolum [INN-Latin]; Normodyne (TN); Sch-19927; Trandate (TN); 2-Hydroxy-5-(1-hydroxy-2-((1-methyl-3-phenylpropyl)amino)ethyl)benzamide; 2-hydroxy-5-[1-hydroxy-2-(4-phenylbutan-2-ylamino)ethyl]benzamide; 2-hydroxy-5-{1-hydroxy-2-[(1-methyl-3-phenylpropyl)amino]ethyl}benzamide; 3-Carboxamido-4-hydroxy-alpha-((1-methyl-3-phenylpropylamino)methyl)benzyl alcohol; 5-(1-Hydroxy-2-(1-methyl-3-phenylpropylamino)ethyl)salicylamide
Indication
Disease Entry ICD 11 Status REF
Hypertension BA00-BA04 Approved [1], [2]
Therapeutic Class
Antihypertensive Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 328.4
Topological Polar Surface Area (xlogp) 3.1
Rotatable Bond Count (rotbonds) 8
Hydrogen Bond Donor Count (hbonddonor) 4
Hydrogen Bond Acceptor Count (hbondacc) 4
ADMET Property
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 1.5 h [3]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
Clearance
The clearance of drug is 1500 mL/min (plasma clearance) and 1100 mL/min (whole blood clearance) [5]
Elimination
Radiolabelled doses of labetalol are 55-60% recovered in the urine and 12-27% recovered in the feces [5]
Half-life
The concentration or amount of drug in body reduced by one-half in 1.7 - 6.1 hours [5]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 104.5296 micromolar/kg/day [6]
Unbound Fraction
The unbound fraction of drug in plasma is 0.5% [7]
Vd
The volume of distribution (Vd) of drug is 805 L [5]
Water Solubility
The ability of drug to dissolve in water is measured as 16 mg/mL [4]
Chemical Identifiers
Formula
C19H24N2O3
IUPAC Name
2-hydroxy-5-[1-hydroxy-2-(4-phenylbutan-2-ylamino)ethyl]benzamide
Canonical SMILES
CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O
InChI
InChI=1S/C19H24N2O3/c1-13(7-8-14-5-3-2-4-6-14)21-12-18(23)15-9-10-17(22)16(11-15)19(20)24/h2-6,9-11,13,18,21-23H,7-8,12H2,1H3,(H2,20,24)
InChIKey
SGUAFYQXFOLMHL-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
3869
ChEBI ID
CHEBI:6343
CAS Number
36894-69-6
DrugBank ID
DB00598
TTD ID
D0A8XN
VARIDT ID
DR01385
INTEDE ID
DR0909
ACDINA ID
D00345

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Adrenergic receptor Alpha-1 (ADRA1) TTG28O6 NOUNIPROTAC Antagonist [8]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Organic anion transporting polypeptide 1A2 (SLCO1A2) DTE2B1D SO1A2_HUMAN Substrate [9]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [10]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [11]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Substrate [12]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Substrate [13]
UDP-glucuronosyltransferase 2B7 (UGT2B7) DEB3CV1 UD2B7_HUMAN Substrate [12]
UDP-glucuronosyltransferase 1A9 (UGT1A9) DE85D2P UD19_HUMAN Substrate [12]
UDP-glucuronosyltransferase 2B4 (UGT2B4) DENUPDX UD2B4_HUMAN Substrate [12]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Labetalol
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Verapamil DMA7PEW Major Increased risk of cardiac depression by the combination of Labetalol and Verapamil. Hypertension [BA00-BA04] [83]
Indapamide DMGN1PW Moderate Increased risk of ventricular arrhythmias by the combination of Labetalol and Indapamide. Hypertension [BA00-BA04] [84]
Trichlormethiazide DMHAQCO Moderate Increased risk of ventricular arrhythmias by the combination of Labetalol and Trichlormethiazide. Hypertension [BA00-BA04] [84]
Felodipine DMOSW35 Moderate Increased risk of cardiac depression by the combination of Labetalol and Felodipine. Hypertension [BA00-BA04] [83]
Hydralazine DMU8JGH Minor Decreased metabolism of Labetalol caused by Hydralazine mediated interference with first-pass metabolism. Hypertension [BA00-BA04] [85]
Hydrochlorothiazide DMUSZHD Moderate Increased risk of hypertriglyceridemia by the combination of Labetalol and Hydrochlorothiazide. Hypertension [BA00-BA04] [84]
Clevidipine butyrate DMW4M97 Moderate Increased risk of cardiac depression by the combination of Labetalol and Clevidipine butyrate. Hypertension [BA00-BA04] [83]
⏷ Show the Full List of 7 DDI Information of This Drug
Coadministration of a Drug Treating the Disease Different from Labetalol (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Labetalol and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [86]
Arn-509 DMT81LZ Moderate Accelerated clearance of Labetalol due to the transporter induction by Arn-509. Acute myeloid leukaemia [2A60] [87]
Scopolamine DMOM8AL Moderate Altered absorption of Labetalol due to GI dynamics variation caused by Scopolamine. Addictive disorder [6C50-6C5Z] [87]
Bepridil DM0RKS4 Moderate Increased risk of cardiac depression by the combination of Labetalol and Bepridil. Angina pectoris [BA40] [83]
Nifedipine DMSVOZT Moderate Increased risk of cardiac depression by the combination of Labetalol and Nifedipine. Angina pectoris [BA40] [83]
Bedaquiline DM3906J Moderate Increased risk of hepatotoxicity by the combination of Labetalol and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [88]
Methylphenobarbital DMDSWAG Moderate Increased metabolism of Labetalol caused by Methylphenobarbital mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [89]
Oxazepam DMXNZM4 Minor Decreased metabolism of Labetalol caused by Oxazepam. Anxiety disorder [6B00-6B0Z] [90]
Zileuton DMVRIC2 Moderate Decreased metabolism of Labetalol caused by Zileuton. Asthma [CA23] [91]
Cariprazine DMJYDVK Moderate Additive hypotensive effects by the combination of Labetalol and Cariprazine. Bipolar disorder [6A60] [92]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Labetalol and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [93]
Atracurium DM42HXN Moderate Additive cardiorespiratory depression effects by the combination of Labetalol and Atracurium. Corneal disease [9A76-9A78] [94]
Mivacurium DM473VD Moderate Additive neuromuscular blocking effects by the combination of Labetalol and Mivacurium. Corneal disease [9A76-9A78] [94]
Pancuronium DMB0VY8 Moderate Additive neuromuscular blocking effects by the combination of Labetalol and Pancuronium. Corneal disease [9A76-9A78] [94]
Tubocurarine DMBZIVP Moderate Additive neuromuscular blocking effects by the combination of Labetalol and Tubocurarine. Corneal disease [9A76-9A78] [94]
Pasireotide DMHM7JS Moderate Increased risk of atrioventricular block by the combination of Labetalol and Pasireotide. Cushing syndrome [5A70] [95]
Sertraline DM0FB1J Moderate Decreased metabolism of Labetalol caused by Sertraline mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [96]
Trimipramine DM1SC8M Moderate Increased plasma concentrations of Labetalol and Trimipramine due to competitive inhibition of the same metabolic pathway. Depression [6A70-6A7Z] [97]
Paroxetine DM5PVQE Moderate Decreased metabolism of Labetalol caused by Paroxetine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [96]
OPC-34712 DMHG57U Moderate Additive hypotensive effects by the combination of Labetalol and OPC-34712. Depression [6A70-6A7Z] [92]
Clomipramine DMINRKW Moderate Increased plasma concentrations of Labetalol and Clomipramine due to competitive inhibition of the same metabolic pathway. Depression [6A70-6A7Z] [97]
Doxepin DMPI98T Moderate Increased plasma concentrations of Labetalol and Doxepin due to competitive inhibition of the same metabolic pathway. Depression [6A70-6A7Z] [97]
Mepenzolate DM8YU2F Moderate Altered absorption of Labetalol due to GI dynamics variation caused by Mepenzolate. Digestive system disease [DE2Z] [87]
Oxybutynine DMJPBAX Moderate Altered absorption of Labetalol due to GI dynamics variation caused by Oxybutynine. Discovery agent [N.A.] [87]
Diazepam DM08E9O Minor Decreased metabolism of Labetalol caused by Diazepam. Epilepsy/seizure [8A61-8A6Z] [90]
Primidone DM0WX6I Moderate Increased metabolism of Labetalol caused by Primidone mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [98]
Phenobarbital DMXZOCG Moderate Increased metabolism of Labetalol caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [98]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Labetalol and Cannabidiol. Epileptic encephalopathy [8A62] [87]
Ethacrynic acid DM60QMR Moderate Increased risk of ventricular arrhythmias by the combination of Labetalol and Ethacrynic acid. Essential hypertension [BA00] [84]
Phenoxybenzamine DM8KSQH Moderate Additive hypotensive effects by the combination of Labetalol and Phenoxybenzamine. Essential hypertension [BA00] [99]
Nicardipine DMCDYW7 Moderate Increased risk of cardiac depression by the combination of Labetalol and Nicardipine. Essential hypertension [BA00] [83]
Tolterodine DMSHPW8 Moderate Altered absorption of Labetalol due to GI dynamics variation caused by Tolterodine. Functional bladder disorder [GC50] [87]
Terbinafine DMI6HUW Moderate Decreased metabolism of Labetalol caused by Terbinafine mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [100]
Propantheline DM2EN6G Moderate Altered absorption of Labetalol due to GI dynamics variation caused by Propantheline. Gastric ulcer [DA60] [87]
Chlorothiazide DMLHESP Moderate Increased risk of ventricular arrhythmias by the combination of Labetalol and Chlorothiazide. Heart failure [BD10-BD1Z] [84]
Furosemide DMMQ8ZG Moderate Increased risk of hypertriglyceridemia by the combination of Labetalol and Furosemide. Heart failure [BD10-BD1Z] [84]
Bumetanide DMRV7H0 Moderate Increased risk of ventricular arrhythmias by the combination of Labetalol and Bumetanide. Heart failure [BD10-BD1Z] [84]
Hydroflumethiazide DMVPUQI Moderate Increased risk of hypertriglyceridemia by the combination of Labetalol and Hydroflumethiazide. Heart failure [BD10-BD1Z] [84]
Rifampin DMA8J1G Moderate Increased metabolism of Labetalol caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [101]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Labetalol and Brentuximab vedotin. Hodgkin lymphoma [2B30] [102]
Efavirenz DMC0GSJ Moderate Increased risk of hepatotoxicity by the combination of Labetalol and Efavirenz. Human immunodeficiency virus disease [1C60-1C62] [103]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Labetalol and Mipomersen. Hyper-lipoproteinaemia [5C80] [104]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Labetalol and Teriflunomide. Hyper-lipoproteinaemia [5C80] [95]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Labetalol and BMS-201038. Hyper-lipoproteinaemia [5C80] [105]
Belladonna DM2RBWK Moderate Altered absorption of Labetalol due to GI dynamics variation caused by Belladonna. Infectious gastroenteritis/colitis [1A40] [87]
Amobarbital DM0GQ8N Moderate Increased metabolism of Labetalol caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [98]
Propiomazine DMKY8V1 Moderate Additive hypotensive effects by the combination of Labetalol and Propiomazine. Insomnia [7A00-7A0Z] [92]
ITI-007 DMUQ1DO Moderate Additive hypotensive effects by the combination of Labetalol and ITI-007. Insomnia [7A00-7A0Z] [92]
Clidinium DMUMQZ0 Moderate Altered absorption of Labetalol due to GI dynamics variation caused by Clidinium. Irritable bowel syndrome [DD91] [87]
Dicyclomine DMZSDGX Moderate Altered absorption of Labetalol due to GI dynamics variation caused by Dicyclomine. Irritable bowel syndrome [DD91] [87]
Glycerol phenylbutyrate DMDGRQO Moderate Decreased metabolism of Labetalol caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme. Liver disease [DB90-DB9Z] [87]
Lumefantrine DM29GAD Moderate Decreased metabolism of Labetalol caused by Lumefantrine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [86]
Chloroquine DMSI5CB Minor Decreased metabolism of Labetalol caused by Chloroquine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [106]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Labetalol and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [107]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Labetalol and Idelalisib. Mature B-cell leukaemia [2A82] [108]
Clofarabine DMCVJ86 Moderate Increased risk of hepatotoxicity by the combination of Labetalol and Clofarabine. Mature B-cell lymphoma [2A85] [109]
Lanthanum carbonate DMMJQSH Moderate Decreased absorption of Labetalol due to formation of complexes caused by Lanthanum carbonate. Mineral absorption/transport disorder [5C64] [95]
Thalidomide DM70BU5 Moderate Increased risk of ventricular arrhythmias by the combination of Labetalol and Thalidomide. Multiple myeloma [2A83] [86]
Siponimod DM2R86O Major Increased risk of bradycardia by the combination of Labetalol and Siponimod. Multiple sclerosis [8A40] [86]
Fingolimod DM5JVAN Major Increased risk of atrioventricular block by the combination of Labetalol and Fingolimod. Multiple sclerosis [8A40] [110]
Ozanimod DMT6AM2 Moderate Increased risk of atrioventricular block by the combination of Labetalol and Ozanimod. Multiple sclerosis [8A40] [111]
Imatinib DM7RJXL Moderate Decreased metabolism of Labetalol caused by Imatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [112]
Promethazine DM6I5GR Moderate Additive hypotensive effects by the combination of Labetalol and Promethazine. Nausea/vomiting [MD90] [92]
Polythiazide DMCH80F Moderate Increased risk of hyperglycemia by the combination of Labetalol and Polythiazide. Oedema [MG29] [84]
Dextropropoxyphene DM23HCX Moderate Decreased metabolism of Labetalol caused by Dextropropoxyphene mediated inhibition of CYP450 enzyme. Pain [MG30-MG3Z] [113]
Biperiden DME78OA Moderate Altered absorption of Labetalol due to GI dynamics variation caused by Biperiden. Parkinsonism [8A00] [87]
Methylscopolamine DM5VWOB Moderate Altered absorption of Labetalol due to GI dynamics variation caused by Methylscopolamine. Peptic ulcer [DA61] [87]
Enzalutamide DMGL19D Moderate Increased metabolism of Labetalol caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [114]
Terazosin DM3JCVS Moderate Additive hypotensive effects by the combination of Labetalol and Terazosin. Prostate hyperplasia [GA90] [99]
Silodosin DMJSBT6 Moderate Additive hypotensive effects by the combination of Labetalol and Silodosin. Prostate hyperplasia [GA90] [99]
Levomepromazine DMIKFEL Moderate Additive hypotensive effects by the combination of Labetalol and Levomepromazine. Psychotic disorder [6A20-6A25] [92]
Fluphenazine DMIT8LX Moderate Additive hypotensive effects by the combination of Labetalol and Fluphenazine. Psychotic disorder [6A20-6A25] [92]
Leflunomide DMR8ONJ Major Increased risk of hepatotoxicity by the combination of Labetalol and Leflunomide. Rheumatoid arthritis [FA20] [95]
Quetiapine DM1N62C Moderate Additive hypotensive effects by the combination of Labetalol and Quetiapine. Schizophrenia [6A20] [92]
Mesoridazine DM2ZGAN Moderate Additive hypotensive effects by the combination of Labetalol and Mesoridazine. Schizophrenia [6A20] [92]
Thioridazine DM35M8J Moderate Additive hypotensive effects by the combination of Labetalol and Thioridazine. Schizophrenia [6A20] [92]
Aripiprazole DM3NUMH Moderate Additive hypotensive effects by the combination of Labetalol and Aripiprazole. Schizophrenia [6A20] [92]
Iloperidone DM6AUFY Moderate Additive hypotensive effects by the combination of Labetalol and Iloperidone. Schizophrenia [6A20] [92]
Paliperidone DM7NPJS Moderate Additive hypotensive effects by the combination of Labetalol and Paliperidone. Schizophrenia [6A20] [92]
Perphenazine DMA4MRX Moderate Additive hypotensive effects by the combination of Labetalol and Perphenazine. Schizophrenia [6A20] [92]
Molindone DMAH70G Moderate Additive hypotensive effects by the combination of Labetalol and Molindone. Schizophrenia [6A20] [92]
Thiothixene DMDINC4 Moderate Additive hypotensive effects by the combination of Labetalol and Thiothixene. Schizophrenia [6A20] [92]
Trifluoperazine DMKBYWI Moderate Additive hypotensive effects by the combination of Labetalol and Trifluoperazine. Schizophrenia [6A20] [92]
Risperidone DMN6DXL Moderate Additive hypotensive effects by the combination of Labetalol and Risperidone. Schizophrenia [6A20] [92]
Amisulpride DMSJVAM Moderate Increased risk of ventricular arrhythmias by the combination of Labetalol and Amisulpride. Schizophrenia [6A20] [87]
Asenapine DMSQZE2 Moderate Additive hypotensive effects by the combination of Labetalol and Asenapine. Schizophrenia [6A20] [92]
Trabectedin DMG3Y89 Moderate Increased risk of hepatotoxicity by the combination of Labetalol and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [87]
Naltrexone DMUL45H Moderate Increased risk of hepatotoxicity by the combination of Labetalol and Naltrexone. Substance abuse [6C40] [115]
Pipecuronium DM5F84A Moderate Additive neuromuscular blocking effects by the combination of Labetalol and Pipecuronium. Tonus and reflex abnormality [MB47] [94]
Vecuronium DMP0UK2 Moderate Additive neuromuscular blocking effects by the combination of Labetalol and Vecuronium. Tonus and reflex abnormality [MB47] [94]
Rocuronium DMY9BMK Moderate Additive neuromuscular blocking effects by the combination of Labetalol and Rocuronium. Tonus and reflex abnormality [MB47] [94]
Methdilazine DMAUHQX Moderate Additive hypotensive effects by the combination of Labetalol and Methdilazine. Vasomotor/allergic rhinitis [CA08] [92]
Trimeprazine DMEMV9D Moderate Additive hypotensive effects by the combination of Labetalol and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [116]
Amiodarone DMUTEX3 Moderate Increased risk of atrioventricular block by the combination of Labetalol and Amiodarone. Ventricular tachyarrhythmia [BC71] [117]
⏷ Show the Full List of 94 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Kyselina citronova E00014 311 Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
methylparaben E00149 7456 Antimicrobial preservative
Propylparaben sodium E00567 23679044 Antimicrobial preservative
Quinoline yellow WS E00309 24671 Colorant
Sodium benzoate E00432 517055 Antimicrobial preservative; lubricant
Sunset yellow FCF E00255 17730 Colorant
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Crospovidone E00626 Not Available Disintegrant
Dextrose anhydrous E00394 107526 Binding agent; Diluent; Flavoring agent; Tonicity agent
Edetate disodium E00186 8759 Complexing agent
Eisenoxyd E00585 56841934 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Hypromellose E00634 Not Available Coating agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 3350 E00652 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 400 E00653 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polyvinyl alcohol E00666 Not Available Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium hydroxide E00234 14798 Alkalizing agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent
Water E00035 962 Solvent
Pregelatinized starch E00674 Not Available Binding agent; Diluent; Disintegrant
⏷ Show the Full List of 28 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Labetalol 300 mg tablet 300 mg Oral Tablet Oral
Labetalol Hydrochloride 100mg tablet 100mg Tablet Oral
Labetalol 100 mg tablet 100 mg Oral Tablet Oral
Labetalol 200 mg tablet 200 mg Oral Tablet Oral
Labetalol Hydrochloride 5mg/ml injectable 5mg/ml Injectable Injection
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7207).
2 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 074787.
3 European Medicines Agency (EMA): DIACOMIT Summary of Product Characteristics
4 BDDCS applied to over 900 drugs
5 Clinical pharmacokinetics of labetalol. Clin Pharmacokinet. 1984 Mar-Apr;9(2):157-67. doi: 10.2165/00003088-198409020-00003.
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
8 Beta-blockers in the treatment of hypertension: are there clinically relevant differences Postgrad Med. 2009 May;121(3):90-8.
9 Involvement of influx and efflux transport systems in gastrointestinal absorption of celiprolol. J Pharm Sci. 2009 Jul;98(7):2529-39.
10 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
11 Comparison of verapamil, diltiazem, and labetalol on the bioavailability and metabolism of imipramine. J Clin Pharmacol. 1992 Feb;32(2):176-83.
12 Regulation of UDP-glucuronosyltransferase (UGT) 1A1 by progesterone and its impact on labetalol elimination. Xenobiotica. 2008 Jan;38(1):62-75.
13 Drug Interactions Flockhart Table
14 Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res. 2009 Mar 1;69(5):1892-900.
15 Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sci. 2010 Aug 14;87(7-8):261-8.
16 Effect of UDP-glucuronosyltransferase (UGT) 1A polymorphism (rs8330 and rs10929303) on glucuronidation status of acetaminophen. Dose Response. 2017 Sep 11;15(3):1559325817723731.
17 UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics. Drug Metab Dispos. 2007 Mar;35(3):371-80.
18 Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. J Clin Pharmacol. 2009 Sep;49(9):1079-90.
19 Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos. 2009 Jan;37(1):229-36.
20 Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9.
21 Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
22 Substrate-dependent modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1) by propofol in recombinant human UGT1A1 and human liver microsomes. Basic Clin Pharmacol Toxicol. 2007 Sep;101(3):211-4.
23 Identification and preliminary characterization of UDP-glucuronosyltransferases catalyzing formation of ethyl glucuronide. Anal Bioanal Chem. 2014 Apr;406(9-10):2325-32.
24 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
25 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
26 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
27 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
28 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
29 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
30 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
31 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
32 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
33 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
34 High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
35 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
36 Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
37 CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
38 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
39 Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
40 Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
41 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
42 Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
43 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
44 Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy. Future Oncol. 2014 Jan;10(1):107-22.
45 Determination of UDP-glucuronosyltransferase UGT2B7 activity in human liver microsomes by ultra-performance liquid chromatography with MS detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Jul 1;870(1):84-90.
46 Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects. Clin Pharmacol Ther. 2008 Apr;83(4):595-600.
47 PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
48 Pitavastatin: a review in hypercholesterolemia. Am J Cardiovasc Drugs. 2017 Apr;17(2):157-168.
49 Troglitazone glucuronidation in human liver and intestine microsomes: high catalytic activity of UGT1A8 and UGT1A10. Drug Metab Dispos. 2002 Dec;30(12):1462-9.
50 Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet. 2005;44(5):467-94.
51 Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmgenomics Pers Med. 2016 Oct 3;9:97-106.
52 Polymorphic expression of UGT1A9 is associated with variable acetaminophen glucuronidation in neonates: a population pharmacokinetic and pharmacogenetic study. Clin Pharmacokinet. 2018 Oct;57(10):1325-1336.
53 Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes. Drug Metab Dispos. 2005 Jul;33(7):1027-35.
54 Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma. Invest New Drugs. 2011 Dec;29(6):1511-4.
55 The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease. Clin Pharmacokinet. 2011 Jan;50(1):1-24.
56 The UDP-glucuronosyltransferase 1A9 enzyme is a peroxisome proliferator-activated receptor alpha and gamma target gene. J Biol Chem. 2003 Apr 18;278(16):13975-83.
57 Methadone inhibits CYP2D6 and UGT2B7/2B4 in vivo: a study using codeine in methadone- and buprenorphine-maintained subjects. Br J Clin Pharmacol. 2012 May;73(5):786-94.
58 Effects of rifampin, cyclosporine A, and probenecid on the pharmacokinetic profile of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants. Int J Clin Pharmacol Ther. 2015 Feb;53(2):115-28.
59 Adult and infant pharmacokinetic profiling of dihydrocodeine using physiologically based pharmacokinetic modeling. Biopharm Drug Dispos. 2019 Nov;40(9):350-357.
60 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
61 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
62 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
63 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
64 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
65 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
66 Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants. J Pharmacol Exp Ther. 2006 Aug;318(2):521-9.
67 Localization of organic anion transporting polypeptide 4 (Oatp4) in rat liver and comparison of its substrate specificity with Oatp1, Oatp2 and Oatp3. Pflugers Arch. 2001 Nov;443(2):188-95.
68 Environmental and genetic factors affecting transport of imatinib by OATP1A2. Clin Pharmacol Ther. 2011 Jun;89(6):816-20.
69 Influence of the flavonoids apigenin, kaempferol, and quercetin on the function of organic anion transporting polypeptides 1A2 and 2B1. Biochem Pharmacol. 2010 Dec 1;80(11):1746-53.
70 Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase. J Pharm Pharmacol. 2005 Oct;57(10):1305-11.
71 Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology. 2006 May;130(6):1793-806.
72 Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of Saquinavir in Hep G2 cells. Mol Pharm. 2004 Jan 12;1(1):49-56.
73 Uptake of enalapril and expression of organic anion transporting polypeptide 1 in zonal, isolated rat hepatocytes. Drug Metab Dispos. 2000 Jul;28(7):801-6.
74 Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver. Gastroenterology. 1995 Oct;109(4):1274-82.
75 Identification of thyroid hormone transporters in humans: different molecules are involved in a tissue-specific manner. Endocrinology. 2001 May;142(5):2005-12.
76 Adventitia removal does not modify the alphaID-adrenoceptors response in aorta during hypertension and ageing. Auton Autacoid Pharmacol. 2009 Jul;29(3):117-33.
77 Reversal of ergotamine-induced vasospasm following methylprednisolone. Clin Toxicol (Phila). 2008 Dec;46(10):1074-6.
78 Orthostatic hypotension in patients with Parkinson's disease: pathophysiology and management. Drugs Aging. 2001;18(7):495-505.
79 Urapidil. A reappraisal of its use in the management of hypertension. Drugs. 1998 Nov;56(5):929-55.
80 Synthesis and structure-activity studies on N-[5-(1H-imidazol-4-yl)-5,6,7,8-tetrahydro-1-naphthalenyl]methanesulfonamide, an imidazole-containing alpha(1A)-adrenoceptor agonist. J Med Chem. 2004 Jun 3;47(12):3220-35.
81 Metazosin tablets (Kenosin) in the treatment of chronic congestive heart failure. Cas Lek Cesk. 1995 Sep 20;134(18):590-3.
82 Antihypertensive and Hypolipidemic Effects of DC-015, a Novel, Potent and Specific alpha(1)-Adrenoceptor Antagonist: Comparison with Prazosin in Spontaneously Hypertensive Rats. J Biomed Sci. 1996 Apr;3(2):108-116.
83 Anastassiades CJ "Nifedipine and beta-blocker drugs." Br Med J 281 (1980): 1251-2. [PMID: 6107167]
84 Dean S, Kendall MJ, Potter S, Thompson MH, Jackson DA "Nadolol in combination with indapamide and xipamide in resistant hypertensives." Eur J Clin Pharmacol 28 (1985): 29-33. [PMID: 3987783]
85 Amemiya M, Tabei K, Furuya H, Sakairi Y, Asano Y "Pharmacokinetics of carteolol in patients with impaired renal function." Eur J Clin Pharmacol 43 (1992): 417-21. [PMID: 1451723]
86 Cerner Multum, Inc. "Australian Product Information.".
87 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
88 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
89 Haglund K, Seideman P, Colliste P, Borg KO, von Bahr C "Influence of pentobarbital on metoprolol plasma levels." Clin Pharmacol Ther 26 (1979): 326-9. [PMID: 466926]
90 Hawksworth G, Betts T, Crowe A, et al "Diazepam/beta-adrenoceptor antagonist interactions." Br J Clin Pharmacol 17 Suppl 1 (1984): s69-76. [PMID: 6146341]
91 Product Information. Zylo Filmtab (zileuton). Abbott Pharmaceutical, Abbott Park, IL.
92 Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
93 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
94 Chapple DJ, Clark JS, Hughes R "Interaction between atracurium and drugs used in anaesthesia." Br J Anaesth 55 Suppl 1 (1983): s17-22. [PMID: 6688011]
95 Canadian Pharmacists Association.
96 Amchin J, Ereshefsky L, Zarycranski W, Taylor K, Albano D, Klockowski PM "Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe." J Clin Pharmacol 41 (2001): 443-51. [PMID: 11304901]
97 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
98 Branch RA, Herman RJ "Enzyme induction and beta-adrenergic receptor blocking drugs." Br J Clin Pharmacol 17 (1984): s77-84. [PMID: 6146342]
99 Chrysant SG "Experience with terazosin administered in combination with other antihypertensive agents." Am J Med 80 (1986): 55-61. [PMID: 2872808]
100 AbdelRahman SM, Gotschall RR, Kauffman RE, Leeder JS, Kearns GL "Investigation of terbinafine as a CYP2D6 inhibitor in vivo." Clin Pharmacol Ther 65 (1999): 465-72. [PMID: 10340911]
101 Kirch W, Rose I, Klingmann I, Pabst J, Ohnhaus EE "Interaction of bisoprolol with cimetidine and rifampicin." Eur J Clin Pharmacol 31 (1986): 59-62. [PMID: 2877885]
102 Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
103 Elsharkawy AM, Schwab U, McCarron B, et al. "Efavirenz induced acute liver failure requiring liver transplantation in a slow drug metaboliser." J Clin Virol 58 (2013): 331-3. [PMID: 23763943]
104 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
105 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
106 Lancaster DL, Adio RA, Tai KK, Simooya OO, Broadhead GD, Tucker GT, Lennard MS "Inhibition of metoprolol metabolism by chloroquine and other antimalarial drugs." J Pharm Pharmacol 42 (1990): 267-71. [PMID: 1974295]
107 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
108 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
109 Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
110 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
111 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
112 Product Information. Gleevec (imatinib mesylate). Novartis Pharmaceuticals, East Hanover, NJ.
113 Janku I, Perlik F, Tkaczykova M, Brodanova M "Disposition kinetics and concentration-effect relationship of metipranolol in patients with cirrhosis and healthy subjects." Eur J Clin Pharmacol 42 (1992): 337-40. [PMID: 1349528]
114 Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
115 Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
116 Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.
117 Leor J, Levartowsky D, Sharon C, Farfel Z "Amiodarone and beta-adrenergic blockers: an interaction with metoprolol but not with atenolol." Am Heart J 16 (1988): 206-7. [PMID: 3394625]